Literature DB >> 28654132

Henoch-Schönlein Purpura: A Literature Review.

Liv Eline Hetland1, Kjærsti Sørensen Susrud, Kim Hein Lindahl, Anette Bygum.   

Abstract

Henoch-Schönlein purpura is the most common childhood vasculitis, but may also affect adults. This article reviews the literature since 2011 on advances in diagnosis, clinical disease manifestations, pathophysiology and treatment of Henoch-Schönlein purpura. The clinical manifestations are thought to arise from IgA depositions in blood vessel walls in the affected organs, mostly skin, gastrointestinal tract, joints and kidneys. Corticosteroids may be effective in rapid resolution of renal manifestations and treating joint and abdominal pain, but they are not proven effective for treating organ manifestations and complications, such as glomerulonephritis, bowel infarction or intussusception. Mycophenolate mofetil or cyclosporine A may be better treatment choices in case of renal involvement. Other immunosuppressive and immunomodulating drugs, such as rituximab and dapsone, are promising, but larger studies are needed to confirm these findings. Cancer screening should be considered in older males diagnosed with Henoch-Schönlein purpura.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28654132     DOI: 10.2340/00015555-2733

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  43 in total

1.  Vasculitis with nonpalpable purpura resembling purpura fulminans.

Authors:  Erina Ono; Koji Takaori; Sayako Maeda
Journal:  Clin Exp Nephrol       Date:  2019-11-27       Impact factor: 2.801

2.  Atypical purpura location in a Sudanese infant with Henoch-Schönlein purpura.

Authors:  Mumen Abdalazim Dafallah; Alaa Abdualazem Dafalla; Esraa Ahmed Ragab; Fawzeia Hamad
Journal:  Sudan J Paediatr       Date:  2021

3.  [Analysis of clinical characteristics of Henoch-Schonlein purpura patients from different altitudes in plateau areas].

Authors:  H Wei; Z Luo
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-18

4.  Cancer-associated vasculitides: a single-centre case series.

Authors:  Hyunsue Do; Jung Yoon Pyo; Sung Soo Ahn; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Clin Rheumatol       Date:  2022-09-09       Impact factor: 3.650

5.  Navigating the initial diagnosis and management of adult IgA vasculitis: A review.

Authors:  Brenna G Kelly; Delaney B Stratton; Iyad Mansour; Bekir Tanriover; Keliegh S Culpepper; Clara Curiel-Lewandrowski
Journal:  JAAD Int       Date:  2022-06-13

6.  Low-dose corticosteroid with mizoribine might be an effective therapy for elderly-onset ISKDC grade VI IgA vasculitis.

Authors:  Hikaru Sugimoto; Shiho Matsuno; Noriko Yamanaka; Wako Yumura; Mitsuyo Itabashi; Takashi Takei
Journal:  CEN Case Rep       Date:  2020-08-04

7.  Henoch-Schönlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center.

Authors:  Izabel M Buscatti; Beatriz B Casella; Nadia E Aikawa; Andrea Watanabe; Sylvia C L Farhat; Lucia M A Campos; Clovis Artur Silva
Journal:  Clin Rheumatol       Date:  2018-01-13       Impact factor: 2.980

8.  Is Henoch-Schönlein purpura a susceptibility factor for functional gastrointestinal disorders in children?

Authors:  Rabia Miray Kisla Ekinci; Sibel Balcı; Okkes Ozgur Mart; Gokhan Tumgor; Sibel Yavuz; Halil Celik; Dilek Dogruel; Derya Ufuk Altintas; Mustafa Yilmaz
Journal:  Rheumatol Int       Date:  2018-08-12       Impact factor: 2.631

9.  Epidemiology and Clinical Characteristics of Henoch-Schönlein Purpura Associated with Mycoplasma pneumoniae Infection in 131 Children in Hubei Province, China.

Authors:  Xiao-Peng Shang; Jian-Gang Wu; Ying Cheng; Hong-Bo Hu
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-05-01       Impact factor: 2.576

10.  Serum-Urine Matched Metabolomics for Predicting Progression of Henoch-Schonlein Purpura Nephritis.

Authors:  Qian Zhang; Ling-Yun Lai; Yuan-Yuan Cai; Ma-Jie Wang; Gaoxiang Ma; Lian-Wen Qi; Jun Xue; Feng-Qing Huang
Journal:  Front Med (Lausanne)       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.